HPV vaccination (2 doses) for preventing cervical cancer
Cost-effectiveness — what published models estimate per unit of health impact
$/DALY
$55–209
WHO-CHOICE modeled
GiveWell
—
no GiveWell model
CE sources
3
Tier A · 457 studies
Source agreement
material
sources differ
Scope to country:All countries
Cost-effectiveness
Estimates are sourced in their native units and shown for comparison, not as literal costs. Sources use different frameworks — see each card for what it represents and how it was derived.
Modeled benchmarks ($/DALY)Tier A · standardized benchmark
WHO-CHOICE estimates are modeled at population-level population coverage, compared against the null set (no intervention) under generalized cost-effectiveness analysis. View WHO-CHOICE methodology →
$/DALY sources differ by 3.8x - a material difference.
Modeled regional estimates — not realized delivery costs.
Published study estimates ($/DALY)Tier B · context only
Tufts GHCEA · 454 studies, varied methods — explore the spread, not a single number.
Health-system
$523
median · n=357
Mixed
$180
median · n=65
Societal
$220
median · n=32
Filter the cohort
$382median of 454 studies · IQR $100–$1,575 · 10 cost-saving
Published study estimates ($/DALY)Tier B · context only
DCP3 (2013 reference)$50median · 3 studies
range $50–$240/DALY. Varied methods — not directly comparable.
Data completeness: not assessed (no country selected) · Evidence confidence: not assessed (no country selected)
Looking for supply/market data for HPV vaccination (2 doses) for preventing cervical cancer? Select a country above, then open its intelligence page.